Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tekturna
aliskiren · 1 trial · 1 indication
as measured by PAH clearance
| Arm | Type | Description |
|---|---|---|
| VTP-27999 | EXPERIMENTAL | - |
| aliskiren | ACTIVE_COMPARATOR | - |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| aliskiren | DRUG | single dose, tablet |
| placebo | DRUG | single dose, tablet |
| VTP-27999 | DRUG | single dose, tablet |
Inclusion Criteria: * Healthy adult male or female, 18-75 years of age * Female subjects must be postmenopausal or surgically sterilized. Postmenopausal females must have had no regular menstrual bleeding for at least one (1) year prior to initial dosing. Menopause will be confirmed by plasma serum...
Aliskiren is a small molecule direct renin inhibitor being studied for effects on renal function. It is an investigational therapy in Phase 1 clinical development. Syndax Pharmaceuticals, Inc. (ticker: SNDX) is the developer. The drug has been evaluated in a single completed Phase 1 trial involving 22 participants.
Aliskiren targets renin (REN), an enzyme in the renin-angiotensin system. As a direct renin inhibitor, aliskiren binds to renin and blocks its activity. This mechanism is intended to reduce angiotensin II formation and influence renal function. The target class is inhibitor, and the molecular target is REN.
Syndax Pharmaceuticals, Inc. (ticker: SNDX) is developing aliskiren. The company is the sponsor of the clinical program evaluating aliskiren in renal function. The drug is a small molecule direct renin inhibitor currently in Phase 1 development.
Aliskiren is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The program includes one completed Phase 1 trial. No active trials are currently listed for aliskiren.
Aliskiren has been studied in one completed Phase 1 trial, NCT01217736, titled "Direct Renin Inhibition and the Kidney." The trial enrolled 22 participants in the United States and evaluated renal function. It was placebo-controlled, not randomized, and not double-blind, and included healthy volunteers.